- Home
- CII vs TNGX Comparison
CII vs TNGX Comparison
Compare CII & TNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CII
- TNGX
- Stock Information
- Founded
- CII 2004
- TNGX 2014
- Country
- CII United States
- TNGX United States
- Employees
- CII N/A
- TNGX N/A
- Industry
- CII Investment Bankers/Brokers/Service
- TNGX Biotechnology: Pharmaceutical Preparations
- Sector
- CII Finance
- TNGX Health Care
- Exchange
- CII Nasdaq
- TNGX Nasdaq
- Market Cap
- CII 870.4M
- TNGX 723.2M
- IPO Year
- CII N/A
- TNGX N/A
- Fundamental
- Price
- CII $22.59
- TNGX $6.94
- Analyst Decision
- CII
- TNGX Strong Buy
- Analyst Count
- CII 0
- TNGX 6
- Target Price
- CII N/A
- TNGX $10.00
- AVG Volume (30 Days)
- CII 78.8K
- TNGX 1.3M
- Earning Date
- CII 01-01-0001
- TNGX 11-05-2025
- Dividend Yield
- CII 6.17%
- TNGX N/A
- EPS Growth
- CII N/A
- TNGX N/A
- EPS
- CII N/A
- TNGX N/A
- Revenue
- CII N/A
- TNGX $24,296,000.00
- Revenue This Year
- CII N/A
- TNGX $6.56
- Revenue Next Year
- CII N/A
- TNGX N/A
- P/E Ratio
- CII N/A
- TNGX N/A
- Revenue Growth
- CII N/A
- TNGX N/A
- 52 Week Low
- CII $16.76
- TNGX $1.03
- 52 Week High
- CII $19.81
- TNGX $11.92
- Technical
- Relative Strength Index (RSI)
- CII 70.43
- TNGX 56.91
- Support Level
- CII $22.15
- TNGX $6.28
- Resistance Level
- CII $22.49
- TNGX $7.05
- Average True Range (ATR)
- CII 0.21
- TNGX 0.41
- MACD
- CII 0.02
- TNGX -0.04
- Stochastic Oscillator
- CII 82.17
- TNGX 57.89
About CII Blackrock Capital and Income Fund Inc.
Blackrock Enhanced Cap&Inc Fund, Inc is a closed-end management investment company. Its objective is to provide total return through a combination of current income and capital appreciation. The trust seeks to achieve its investment objective by investing a majority of its total assets in a portfolio of equity securities of U.S. and foreign issuers.
About TNGX Tango Therapeutics Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.